Inolac3.35 gm/5 ml

Established / FDA-approved use

• Treatment of chronic constipation: Inolac 3.35 gm/5 ml is indicated for patients with chronic idiopathic constipation who have not responded adequately to diet and lifestyle measures.

Guideline-supported use

• Prevention and treatment of hepatic (portosystemic) encephalopathy, including the stages of hepatic pre-coma and coma, in patients with liver disease. This use is supported by hepatology practice guidelines (e.g., AASLD/EASL) and is a standard first-line therapy for hepatic encephalopathy.

Adjunct use

• Inolac 3.35 gm/5 ml may be used as an adjunct with other agents (such as rifaximin) for secondary prevention of recurrent hepatic encephalopathy when Inolac 3.35 gm/5 ml alone is insufficient.

Inolac 3.35 gm/5 ml is not an antibiotic and has no role in treating infections.

Inolac 3.35 gm/5 ml is available in Bangladesh mainly as an oral solution containing Inolac 3.35 gm/5 ml 3.35 g per 5 mL (equivalent to a 10 g/15 mL strength), supplied in bottles of various sizes for oral use. Some manufacturers also market crystalline Inolac 3.35 gm/5 ml powder for preparation of solutions. Strength and pack size vary by manufacturer; always check the product label for the exact concentration.

Inolac 3.35 gm/5 ml is a synthetic, non-absorbable disaccharide (a combination of the sugars galactose and fructose) used as an osmotic laxative and as an ammonia-lowering agent. Because Inolac 3.35 gm/5 ml is not broken down or absorbed in the small intestine, it passes intact into the colon, where it is metabolized by colonic bacteria into low-molecular-weight organic acids. These acids increase osmotic pressure within the colon, drawing water into the bowel lumen, softening the stool, and increasing stool frequency. The same colonic acidification also converts absorbable ammonia (NH3) into non-absorbable ammonium ions (NH4+), which are then trapped in the colon and excreted, lowering blood ammonia levels. Inolac 3.35 gm/5 ml is widely used both for chronic constipation and for the prevention and management of hepatic encephalopathy.

Osmotic (hyperosmotic) laxative; ammonia-lowering agent — synthetic disaccharide

Inolac 3.35 gm/5 ml is a synthetic disaccharide of galactose and fructose. It is not hydrolyzed by intestinal enzymes and is minimally absorbed from the small intestine, so it reaches the colon essentially unchanged.

Laxative action

In the colon, bacterial flora metabolize Inolac 3.35 gm/5 ml into low-molecular-weight organic acids (lactic, acetic, and small amounts of formic acid). These acids lower colonic pH and increase osmotic pressure, causing water retention in the bowel lumen. This softens the stool, increases stool volume, and stimulates peristalsis, producing a bowel movement typically within 24–48 hours.

Ammonia-lowering action

The acidification of colonic contents converts absorbable ammonia (NH3) into the poorly absorbable ammonium ion (NH4+), trapping nitrogenous waste in the colon lumen for elimination in the stool. Inolac 3.35 gm/5 ml also reduces the population of ammonia-producing (urease-containing) intestinal bacteria and, through its cathartic effect, reduces colonic transit time, further limiting ammonia absorption. This mechanism underlies its efficacy in reducing blood ammonia and improving mental status in hepatic encephalopathy.

Inolac 3.35 gm/5 ml oral solution may be taken directly or mixed with water, fruit juice, or milk to improve palatability, with or without food. Use a proper measuring device (dosing cup/spoon) rather than a household spoon for accuracy. It may take 24–48 hours to see the full laxative effect for constipation, so it should not be taken solely for rapid relief. For hepatic encephalopathy, doses are usually spread through the day and adjusted by the treating physician based on stool frequency and consistency. If a dose is missed, take it as soon as remembered unless it is close to the next dose; do not double the dose. Do not exceed the dose or duration advised by the physician.

• Non-absorbable antacids (e.g., aluminum hydroxide): may inhibit the colonic acidification produced by Inolac 3.35 gm/5 ml, potentially reducing its effectiveness in hepatic encephalopathy; concurrent use should be monitored.
• Neomycin and other antibiotics used for hepatic encephalopathy: when combined with Inolac 3.35 gm/5 ml, may theoretically reduce the colonic bacterial fermentation needed to produce Inolac 3.35 gm/5 ml's acidifying effect; clinical monitoring of response is advised, though the combination is still commonly used.
• Other laxatives: concurrent use with other laxatives is generally discouraged as it makes it difficult to titrate Inolac 3.35 gm/5 ml to the desired stool frequency and increases the risk of diarrhea and electrolyte disturbance.
• Diuretics and corticosteroids: concomitant use with Inolac 3.35 gm/5 ml may increase the risk of hypokalemia if Inolac 3.35 gm/5 ml-induced diarrhea occurs; electrolytes should be monitored, particularly with excessive dosing.

Common (especially at the start of therapy, usually transient and dose-related): abdominal bloating, flatulence, belching, and abdominal cramping.

Less common: nausea, vomiting, and diarrhea, particularly with excessive dosing.

Uncommon/with excessive or prolonged use: electrolyte imbalance (e.g., low potassium, low sodium) related to fluid loss from diarrhea — see Precautions and Warnings.

Inolac 3.35 gm/5 ml is minimally absorbed systemically and is generally considered a low-risk laxative option during pregnancy; nevertheless, as with any medicine in pregnancy, Inolac 3.35 gm/5 ml should be used only if clearly needed and as directed by a physician, with the potential benefit weighed against any potential risk. There are no adequate, well-controlled studies in pregnant women.

Data on excretion of Inolac 3.35 gm/5 ml into breast milk are limited, but due to its negligible systemic absorption, it is generally considered acceptable for use during breastfeeding under medical guidance. A physician or pharmacist should be consulted before use in pregnancy or lactation.

• Electrolyte disturbance: Excessive or prolonged use of Inolac 3.35 gm/5 ml can cause significant diarrhea leading to dehydration and electrolyte imbalances (e.g., hypokalemia, hypernatremia); monitor patients on high-dose or long-term therapy, especially the elderly and those with pre-existing electrolyte abnormalities.
• Diabetes mellitus: Inolac 3.35 gm/5 ml solutions contain small amounts of free sugars (galactose, lactose); use with caution and monitor blood glucose in diabetic patients, particularly with long-term or high-dose use.
• Hepatic encephalopathy dosing: Doses used for hepatic encephalopathy are considerably higher than for simple constipation and must be carefully titrated by a physician to achieve 2–3 soft stools per day; self-adjustment of dose in this setting is not recommended.
• Electrocautery procedures: If colonic preparation with Inolac 3.35 gm/5 ml is used before a procedure involving electrocautery, adequate bowel cleansing with non-fermentable solutions should be ensured beforehand, as fermentation gases can theoretically pose a risk during such procedures.
• Galactose-restricted diets: Not for use in patients requiring a galactose-free diet — see Contraindications.

Overdose with Inolac 3.35 gm/5 ml chiefly causes exaggerated laxative effects: severe diarrhea, abdominal cramping, and consequent loss of fluid and electrolytes. If overdose is suspected, discontinue Inolac 3.35 gm/5 ml, ensure adequate fluid intake, and seek immediate medical attention or contact a poison control center/emergency services, particularly if there are signs of dehydration (dizziness, reduced urination) or electrolyte disturbance. Do not attempt to manage a significant overdose with home remedies alone.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep out of reach of children.

• Renal impairment: No dose adjustment is generally required, as systemic absorption of Inolac 3.35 gm/5 ml is minimal.
• Hepatic impairment: Patients with liver disease and hepatic encephalopathy are a primary target population for Inolac 3.35 gm/5 ml; dosing should be titrated by the treating physician with monitoring of stool frequency, mental status, and electrolytes.
• Elderly: May be more susceptible to fluid and electrolyte disturbances from excessive dosing; use the lowest effective dose and monitor closely.
• Diabetics: Use with caution due to small sugar content; monitor blood glucose with prolonged use — see Precautions and Warnings.
• Pregnancy and lactation: See Pregnancy and Lactation section.

For constipation, Inolac 3.35 gm/5 ml is typically used for short courses initially, with response assessed within 24–48 hours; if there is no improvement within 2–3 days, a physician should be consulted. Inolac 3.35 gm/5 ml can be continued for longer-term management of chronic constipation under medical supervision, with periodic reassessment. For hepatic encephalopathy, Inolac 3.35 gm/5 ml is generally used long-term as maintenance therapy, with the dose continuously titrated by the treating physician to maintain 2–3 soft stools per day; duration is determined by the underlying liver disease and clinical response.

Osmotic laxatives; ammonia-detoxicating agents (synthetic disaccharides)

Inolac 3.35 gm/5 ml reaches the colon unabsorbed, where bacterial fermentation converts it into organic acids that osmotically draw water into the bowel (laxative effect) and acidify the colonic contents, trapping ammonia as non-absorbable ammonium ions for excretion (ammonia-lowering effect). See Pharmacology for full detail.

B

The manufacturer's labeling for Inolac 3.35 gm/5 ml oral solution states that safety and effectiveness in pediatric patients for constipation have not been formally established. Despite this, Inolac 3.35 gm/5 ml is widely and commonly used off-label in children (including infants) under medical supervision for functional constipation, with the dose individualized by the treating physician according to the child's age and weight and titrated to achieve a soft, comfortable stool pattern. Inolac 3.35 gm/5 ml is also used in children with hepatic encephalopathy due to liver disease, again under close physician supervision. Parents/caregivers should not adjust the dose without medical advice, and should consult a pediatrician before use in infants and young children.